Scientific paper - Letter
Ruxolitinib withdrawal due to the COVID-19
Leukemia, 35 (2021), 4; 1218. https://doi.org/10.1038/s41375-021-01214-4


Linked objects
COVID-19 | Virtual collection
Cite this document

Lucijanić, M. & Kušec, R. (2021). Ruxolitinib withdrawal due to the COVID-19. Leukemia, 35. (4), 1218. doi: 10.1038/s41375-021-01214-4

Lucijanić, Marko and Rajko Kušec. "Ruxolitinib withdrawal due to the COVID-19." Leukemia, vol. 35, no. 4, 2021, p. 1218. https://doi.org/10.1038/s41375-021-01214-4

Lucijanić, Marko and Rajko Kušec. "Ruxolitinib withdrawal due to the COVID-19." Leukemia 35, no. 4 (2021): 1218. https://doi.org/10.1038/s41375-021-01214-4

Lucijanić, M. and Kušec, R. (2021) 'Ruxolitinib withdrawal due to the COVID-19', Leukemia, 35(4), p. 1218. doi: 10.1038/s41375-021-01214-4

Lucijanić M, Kušec R. Ruxolitinib withdrawal due to the COVID-19. Leukemia [Internet]. 2021 March 17 [cited 2024 February 29];35(4):1218. doi: 10.1038/s41375-021-01214-4

M. Lucijanić and R. Kušec, "Ruxolitinib withdrawal due to the COVID-19", Leukemia, vol. 35, no. 4, p. 1218, March 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:466215. [Accessed: 29 February 2024]

Please login to the repository to save this object to your list.